S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results

Reneo Pharmaceuticals (RPHM) Earnings Date, Estimates & Call Transcripts

$1.66
+0.02 (+1.22%)
(As of 02/27/2024 ET)
Skip Charts & View Estimated and Actual Earnings Data

RPHM Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RPHM Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Reneo Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242($0.59)($0.58)($0.59)
Q2 20242($0.65)($0.58)($0.62)
Q3 20242($0.73)($0.60)($0.67)
Q4 20243($0.81)$0.04($0.48)
FY 20249($2.78)($1.72)($2.35)

RPHM Earnings Date and Information

Reneo Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 25th, 2024 based off prior year's report dates.

Reneo Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
3/25/2024
Estimated)
------- 
11/13/2023Q3 2023($0.60)($0.57)+$0.03($0.57)--
8/10/2023Q2 2023($0.55)($0.65)($0.10)($0.65)--
5/11/2023Q1 2023($0.63)($0.60)+$0.03($0.60)--
3/27/2023Q4 2022($0.59)($0.56)+$0.03($0.56)--
11/8/2022Q3 2022($0.58)($0.53)+$0.05($0.53)--
8/9/2022Q2 2022($0.60)($0.50)+$0.10($0.50)--
5/10/2022Q1 2022($0.54)($0.53)+$0.01($0.53)--
3/23/2022Q4 2021($0.59)($0.43)+$0.16($0.43)--
11/11/2021Q3 2021($0.47)($0.52)($0.05)($0.52)--
8/11/2021Q2 2021($0.37)($0.43)($0.06)($0.43)--
5/19/2021Q1 2021($0.38)($3.48)($3.10)($3.48)--












Reneo Pharmaceuticals Earnings - Frequently Asked Questions

When is Reneo Pharmaceuticals's earnings date?

Reneo Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 25th, 2024 based off last year's report dates. Learn more on RPHM's earnings history.

How much profit does Reneo Pharmaceuticals generate each year?

Reneo Pharmaceuticals (NASDAQ:RPHM) has a recorded net income of -$51.96 million. RPHM has generated -$2.38 earnings per share over the last four quarters.

What is Reneo Pharmaceuticals's EPS forecast for next year?

Reneo Pharmaceuticals's earnings are expected to grow from ($2.44) per share to ($0.77) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:RPHM) was last updated on 2/28/2024 by MarketBeat.com Staff